TP53 and malignant colon neoplasm: We report herewith that inhibition of GCS, via <i>UGCG</i> knockout and using an inhibitor (Genz-161), effectively re-sensitizes drug resistance and diminishes CSCs in colon cancer cells carrying the homozygous p53 R273H mutation.